MedImmune's Sales Fall Short

Although MedImmune Inc. (MEDI) swung to a fourth quarter profit of 50 cents per share compared with a loss of 9 cents per share a year earlier, sales of its respiratory medication Synagis were weaker than expected. The stock price tumbled $2.97 to close at $31.04.